Attractions and challenges of Poland’s pharmaceutical market

17 July 2014

Not only is Poland the largest pharmaceutical market in the Central & Eastern Europe region and the sixth largest in Europe, with a market value of some $8.1 billion, it is also a hub for production and functional activities.

According to Healthcare and Life Sciences Review Poland 2014, a new report now available from PharmaBoardroom, with a Gross Domestic Product (GDP) growth of 3% forecast by the Organization for Economic Cooperation and Development (OECD), and the first positive balance of trade in 2013 since its accession to the European Union, there are also clear signs of economic momentum.

Poland has lowest innovate and generic drug prices in Europe

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >